ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These results suggested that greater efficacy may have been achieved if asciminib alone or in combination with a BCR‐ABL inhibitor had been used in the same patient at the initial onset of CML, before BCR‐ABL inhibitor resistance development.